Castellano, Daniel <br/><br/>
The role of RANK-ligand inhibition in cancer: the story of denosumab.  [electronic resource] 

 -  The oncologist  2011 
 - 136-45 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2010-0154  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Bone Remodeling--drug effects<br/>Breast Neoplasms--pathology<br/>Clinical Trials as Topic<br/>Denosumab<br/>Humans<br/>Male<br/>Multiple Myeloma--pathology<br/>Osteoclasts--drug effects<br/>Prostatic Neoplasms--pathology<br/>RANK Ligand--antagonists & inhibitors<br/>Receptor Activator of Nuclear Factor-kappa B--metabolism<br/>Treatment Outcome